This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
B cell lymphoma	Enhancer of zeste homolog 2 (EZH2)	<p>An <i>in vitro</i> study suggests that EZH2 inhibitors may help treat a subset of B cell lymphomas. Somatic mutations at tyrosine 641 (Tyr641) in the histone methyltransferase EZH2 are known to exist in a subset of diffuse large B cell lymphomas. <i>In vitro</i>, Tyr641 mutants of EZH2 had greater trimethylating activity than the wild-type enzyme. The researchers have identified small molecule inhibitors of EZH2, and next steps include testing the compounds in preclinical mouse models of B cell lymphomas.</p> <p>SciBX 3(47); doi:10.1038/scibx.2010.1405 Published online Dec. 9, 2010</p>	Patent application filed covering target, diagnostics and therapeutics; unavailable for licensing	<p>Sneeringer, C.J. <i>et al.</i> <i>Proc. Natl. Acad. Sci. USA</i>; published online Nov. 15, 2010; doi:10.1073/pnas.1012525107</p> <p>Contact: Robert A. Copeland, Epizyme Inc., Cambridge, Mass. e-mail: RCopeland@epizyme.com</p> <p>Contact: Victoria M. Richon, same affiliation as above e-mail: VRichon@epizyme.com</p>